Publications - Phar LLC

Featured Publications

Tapering thrombopoietin receptor agonists in primary immune thrombocytopenia: Expert consensus based on the RAND/UCLA modified Delphi panel method

Cuker A, Despotovic JM, Grace RF, Kruse C, Lambert MP, Liebman HA, Lyons RM, McCrae KR, Pullarkat V, Wasser JS, Beenhouwer D, Gibbs SN, Yermilov I, Broder MS

Research and Practice in Thrombosis and Haemostasis

2020

Download

Economic Burden of Neurologic Toxicities Associated with Treatment of Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma in the United States

Broder MS, Ma Q, Yan T, Zhang J, Chang E, Kuzan D, Eldjerou L

American Health & Drug Benefits

2020

Download

Development of a Severity Classification System for Sickle Cell Disease

Shah N, Beenhouwer D, Broder MS, Bronte-Hall L, De Castro LM, Gibbs SN, Gordeuk VR, Kanter J, Klings ES, Lipato T, Manwani D, Scullin B, Yermilov I, Smith WR

ClinicoEconomics and Outcomes Research

2020

Download

The patient journey toward a diagnosis of hereditary transthyretin (ATTRv) amyloidosis

Vera-Llonch M, Reddy SR, Chang E, Tarbox MH, Pollock M

Orphanet Journal of Rare Diseases

2021

Download

2020

Tapering thrombopoietin receptor agonists in primary immune thrombocytopenia: Expert consensus based on the RAND/UCLA modified Delphi panel method

Economic Burden of Neurologic Toxicities Associated with Treatment of Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma in the United States

Development of a Severity Classification System for Sickle Cell Disease

The patient journey toward a diagnosis of hereditary transthyretin (ATTRv) amyloidosis

Hospital Share of Profits from Physician-Administered Medicines

Projected Lifetime Clinical Value of a Multicancer Early Detection Test

Real-World Impact of Disease on Functioning and Activity: A Cross-Sectional Study of the National Health and Nutrition Examination Survey

Spending on Medicines Accounts for a Small Share of Hospital Spending Increases

The economic burden of caregiving in epilepsy: An estimate based on a survey of US caregivers

Costs associated with unplanned readmissions among patients with heart failure with and without hyponatremia

Healthcare Policy Changes in Osteoporosis Can Improve Outcomes and Reduce Costs in the United States

How does the Cox maze procedure compare? Cost-effectiveness analysis of alternative treatments of atrial fibrillation

Modeling the Mortality Impact of Budget Thresholds

Protecting the gains: What changes are needed to prevent a reversal of the downward cardiovascular disease mortality trend?

A Conversational War of Attrition

Bending the curve with patient identification and treatment in osteoporosis

Budget impact analysis of long-acting injectable aripiprazole once-monthly 400 mg in bipolar I disorder in the USA

Cost-effectiveness of long-acting injectable aripiprazole once-monthly 400 mg in bipolar I disorder in the USA

Defining Value-Based Pricing of Drugs

Systematic bias in predictions of new drugs’ budget impact: analysis of a sample of recent US drug launches

The potential value of rapid, cloud-enabled onsite testing for the diagnosis of rheumatoid arthritis in the United States

Utilization and budget impact of tolvaptan in the inpatient setting among patients with heart failure and hyponatremia

A systematic literature review of methods of incorporating mortality in cost effectiveness analyses of lipid-lowering therapies

Budget Impact Analysis Comparing Aripiprazole and Aripiprazole Lauroxil Based on Real-World Dosing Patterns

Budget Impact Analysis of Long-Acting Injectable Aripiprazole Once-Monthly 400 mg in Bipolar I Disorder

Budget Impact of Increased Utilization of Palonosetron for the Control of Chemotherapy Induced Nausea and Vomiting in Managed Care

Budget impact of somatostatin analogs as treatment for metastatic gastroenteropancreatic neuroendocrine tumors in US hospitals

Cost Effectiveness of Bronchial Thermoplasty for Treatment of Severe Asthma Patients in Scotland